- Home
- PDFS vs ELVN Comparison
PDFS vs ELVN Comparison
Compare PDFS & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDFS | ELVN |
|---|---|---|
| Founded | 1992 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 2.3B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PDFS | ELVN |
|---|---|---|
| Price | $52.15 | $43.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $39.67 | ★ $43.40 |
| AVG Volume (30 Days) | 554.2K | ★ 641.7K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $18.92 | N/A |
| P/E Ratio | $426.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.35 | $14.79 |
| 52 Week High | $56.46 | $48.53 |
Technical Indicators
Market Signals| Indicator | PDFS | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 67.06 | 57.32 |
| Support Level | $25.86 | $16.84 |
| Resistance Level | N/A | $48.53 |
| Average True Range (ATR) | 3.68 | 2.45 |
| MACD | 0.64 | -0.46 |
| Stochastic Oscillator | 77.06 | 54.83 |
Price Performance
Historical ComparisonAbout PDFS PDF Solutions Inc.
PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.